The present study investigated comparatively the relation between host age and age-specific incidence rate (ASIR) of breast cancer in the United Kingdom and Japan. Comparison was also made between breast cancer and 5 non-mammary neoplasias as regards the cancer incidence/age profile. The results obtained are as follows: 1) the ASIR profile of breast cancer in the age range of 22.5 years to 47.5 years was characterized by a rapid rise versus age which was common between the United Kingdom and Japan. By use of the log-log plot, the growth of breast cancer risk was found to be quasi-exponential, and the above time range was termed the stage of exponential growth. 2) From 47.5 years of age on, the stage of stagnation ensued: the ASIR for the United Kingdom kept on rising with a much reduced inclination, whereas that for Japan followed the way of gradual decline. In the log-log plot, the junction between the 2 stages was recognized as a distinct break point. 3) A similar two-stage structure was found in the ASIR profiles of cancers of the stomach, lung, cervix uteri, and corpus uteri. The break points for the first 2 neoplasias were located at senescent ages, and those for cervical cancer and endometrial cancer were located at the pre- and peri-menopausal ages respectively (27.5-32.5 and 52.5 years). The profile of lymphoid leukemia gave 2 distinct surges at the ages of infancy and senescence, regardless of the country. The significance of the break point in the ASIR profile of breast cancer was discussed in relation to the two-step carcinogenesis theory.
Download full-text PDF |
Source |
---|
BMC Cancer
January 2025
Young Academy of Gynecologic Oncology (JAGO), Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO), Berlin, Germany.
Background: The integration of immune checkpoint inhibitors (ICIs) into routine gynecologic cancer treatment requires a thorough understanding of how to manage immune-related adverse events (irAEs) to ensure patient safety. However, reports on real-world clinical experience in the management of ICIs in gynecologic oncology are very limited. The aim of this survey was to provide a real-world overview of the experiences and the current state of irAE management of ICIs in Germany, Switzerland, and Austria.
View Article and Find Full Text PDFBMC Cancer
January 2025
Division de la Recherche Clinique, Centre Jean PERRIN, 58 rue Montalembert, Clermont-Ferrand, 63011, France.
Background: Over the past twenty years, the post-cancer rehabilitation has been developed, usually in a hospital setting. Although this allows better care organization and improved security, it is perceived as stressful and restrictive by the "cancer survivor". Therefore, the transfer of benefits to everyday life is more difficult, or even uncertain.
View Article and Find Full Text PDFBreast Cancer
January 2025
Tepe Prime, MKA Breast Cancer Clinic, 06800, Ankara, Turkey.
Breast Cancer Res Treat
January 2025
Google Health, 1600 Amphitheatre Pkwy, Mountain View, CA, 94043, USA.
Purpose: Many breast centers are unable to provide immediate results at the time of screening mammography which results in delayed patient care. Implementing artificial intelligence (AI) could identify patients who may have breast cancer and accelerate the time to diagnostic imaging and biopsy diagnosis.
Methods: In this prospective randomized, unblinded, controlled implementation study we enrolled 1000 screening participants between March 2021 and May 2022.
Mol Biol Rep
January 2025
Department of Clinical Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Background: The identification of circulating potential biomarkers may help earlier diagnosis of breast cancer, which is critical for effective treatment and better disease outcomes. We aimed to study the role of circ-FAF1 as a diagnostic biomarker in female breast cancer using peripheral blood samples of these patients, and to investigate the relation between circ-FAF1 and different clinicopathological features of the included patients.
Methods And Results: This case-control study enrolled 60 female breast cancer patients and 60 age-matched healthy control subjects.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!